IP Verse

Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes

Patent No. EP2069374 (titled "Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes") was filed by Astrazeneca on Jun 21, 2007. The application was issued on Jul 28, 2021.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
LEK PHARMACEUTICALS DDApr 30, 2015MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2069374

ASTRAZENECA
Application Number
EP07784499A
Filing Date
Jun 21, 2007
Status
Patent Maintained As Amended
Jun 25, 2021
Publication Date
Jul 28, 2021
External Links
Slate, Register , Google Patents